Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
复制标题
DOI：
10.5114/wo.2018.73878
复制
发表时间：
2018-03
期刊：
影响因子：
--
通讯作者：
Kieda C
中科院分区：
文献类型：
--
作者：
Brodaczewska KK;Szczylik C;Kieda C
肾细胞癌（RCC）是一种高度血管化的肿瘤，目前的治疗主要依赖于抗血管生成治疗方案。这些包括酪氨酸激酶抑制剂（TKI）和抗VEGF单克隆抗体。虽然这些策略旨在抑制血管形成以控制肿瘤生长，但这些疗法的效果要广泛得多，因为影响血管结构会深刻改变肿瘤块的微环境。本综述的目的是概述抗血管生成治疗（主要是TKI）对RCC微环境免疫组分形成的全球影响的现有知识。收集支持通过抗血管生成疗法修饰免疫的数据，以揭示血管生成调节作为免疫疗法中辅助抗癌方法的策略的潜力。
Current therapies of renal cell carcinoma (RCC), a highly vascularised tumour, mostly rely on anti-angiogenic treatment options. These include tyrosine kinase inhibitors (TKIs) and anti-VEGF monoclonal antibodies. Although these strategies aim at restraining vascularisation to control tumour growth, the effects of such therapies are much wider, as affecting the vessel structure deeply modifies the microenvironment of the tumour mass. The aim of this review is to provide an overview of current knowledge on the global effects of anti-angiogenic treatment, mostly TKIs, on the shaping of the immune component of the RCC microenvironment. The data supporting the modification of immunity by anti-angiogenic therapies are collected to reveal the potential of angiogenesis modulation as a strategy for the adjuvant anti-cancer approach in immunotherapy.